Współczesna Onkologia

Precision oncology for lung cancer in the Federation of Bosnia and Herzegovina: current access and unmet needs

Krešimir Tomić 1
,
Ana Parić 1
,
Inga Marijanovic 1
,
Kristina Galić 1
,
Alma Mekić Abazović 2
,
Šefika Umihanić 3
,
Semir Bešlija 4
,
Timur Cerić 4
,
Semir Vranic 5

  1. University Clinical Hospital Mostar, Bosnia and Herzegovina

  2. Cantonal Hospital Zenica, Bosnia and Herzegovina

  3. University Clinical Centre Tuzla, Bosnia and Herzegovina

  4. Clinical Centre, University of Sarajevo, Bosnia and Herzegovina

  5. Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar

Contemp Oncol (Pozn) 2026; 30 (3)

DOI: https://doi.org/10.5114/wo.2026.165636
Data publikacji online: 2026/10/19
Article file
Precision oncology.pdf
  1. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, (2024). Available from: https://gco.iarc.who.int/today (accessed: 17.04.2026).
  2. World Health Organization. Tobacco control fact sheet: Bosnia and Herzegovina. Copenhagen: WHO Regional Office for Europe. Available from: https://cdn.who.int/media/docs/librariesprovider2/euro-health-topics/tobacco/tobacco-control-fact-sheet-bosniaherzegovina.pdf (accessed: 17.04.2026).
  3. Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C, et al. Advances in molecular pathology and therapy of non-small cell lung cancer. Sig Transduct Target Ther 2025; 10: 186.
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2026.
  5. Bandura A, Dinh PT, Wrona A, Konopa K, Dziadziuszko R. Treatment of oligometastatic non-small cell lung cancer with radiotherapy - single-centre experience. Contemp Oncol (Pozn) 2025; 29: 179-187.
  6. Zer A, Ahn MJ, Barlesi F, Bubendorf L, De Ruysscher D, Garrido P, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025; 361: 1245-1262.
  7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
  8. Batra U, Nathany S. Biomarker testing in lung cancer: from bench to bedside. Oncol Rev 2024; 18: 1445826.
  9. Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numata T, et al. Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene. Contemp Oncol (Pozn) 2025; 29: 93-98.
  10. Kurtovic-Kozaric A, Vranic S, Kurtovic S, Hasic A, Kozaric M, Granov N, et al. Lack of access to targeted cancer treatment modalities in the developing world in the era of precision medicine: real-life lessons from Bosnia. J Glob Oncol 2018; 4: 1-5.
  11. Solomon BJ, Drilon A, Lin JJ, Bazhenova L, Goto K, De Langen J, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I/II TRIDENT-1 trial. Ann Oncol 2023; 34: S787-788.
  12. Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016; 17: 452-463.
  13. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med 2022; 387: 120-131.
  14. Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 Deletion or L858R Mutations. JCO 2022; 40: 3162-3171.
  15. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-222.
  16. Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17: 577-589.
  17. Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK -positive non-small-cell lung cancer. N Engl J Med 2024; 390: 1265-1276.
  18. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829-838.
  19. Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, et al. Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med 2023; 389: 2039-2051.
  20. Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus lazertinib in previously untreated EGFR -mutated advanced NSCLC. N Engl J Med 2024; 391: 1486-1498.
  21. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Holmskov Hansen K, Kim SW, et al. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA). JCO 2016; 34: 9007.
  22. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018; 379: 2027-2039.
  23. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-Mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 2020; 383: 944-957.
  24. Shaw AT, Ou SHI, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1 – rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-1971.
  25. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
  26. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18: 1454-1466.
  27. Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G, Shum E, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-lung05 study. JCO 2025; 43: 1254-1265.
  28. Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-lung01 study. JCO 2025; 43: 260-272.
  29. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-155.
  30. Demetri GD, Paz-Ares L, Farago AF, Liu SV, Chawla SP, Tosi D, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol 2018; 29: viii713.
  31. Hong DS, Xu RH, Shen L, Dierselhuis MP, Orbach D, McDermott R, et al. Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Open 2025; 10: 105110.
  32. Li W, Xiong A, Yang N, Fan H, Yu Q, Zhao Y, et al. Efficacy and safety of taletrectinib in chinese patients with ROS1+ non-small cell lung cancer: the phase II TRUST-I study. JCO 2024; 42: 2660-2670.
  33. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378: 731-739.
  34. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020; 383: 813-824.
  35. Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O’Reilly EM, et al. Efficacy of Zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med 2025; 392: 566-576.
  36. Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol 2021; 7: 1617.
  37. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
  38. Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, et al. FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res 2016; 22: 5171-5176.
  39. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-2177.
  40. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in Caucasian EGFR mutation- positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014; 110: 55-62.
  41. Shaw AT, Bauer TM, De Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020; 383: 2018-2029.
  42. Riely GJ, Ahn MJ, Clarke J, Dagogo-Jack I, Felip E, Gelsomino F, et al. LBA56 updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Ann Oncol 2024; 35: S1246-1247.
  43. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018; 19: 1654-1667.
  44. Liu G, Yang N, Choi CM, Ohe Y, Sugawara S, Yanagitani N, et al. MA06.03 efficacy and safety of taletrectinib in patients with ROS1+ non-small cell lung cancer: the Global TRUST-II study. J Thor Oncol 2024; 19: S72-73.
  45. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16: 763-774.
  46. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR – mutated non-small-cell lung cancer. N Engl J Med 2020; 383: 1711-1723.
  47. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
  48. Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al. Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2017; 28: v637.
  49. Sequist LV, Yang JCH, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. JCO 2013; 31: 3327-3334.
  50. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021; 22: 959-969.
  51. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet; 384: 665-673.
  52. Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Chiu CH, et al. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). JCO 2019; 37: 9000.
  53. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med 2024; 390: 118-131.
  54. Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, et al. Sevabertinib in advanced HER2 -mutant non-small-cell lung cancer. N Engl J Med 2025; 393: 1819-1832.
  55. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021; 384: 2371-2381.
  56. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med 2020; 383: 931-943.
  57. Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. JCO 2023; 41: 4852-4863.
  58. Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med 2025; 392: 2321-2333.
  59. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301.
  60. Herbst RS, Giaccone G, De Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020; 383: 1328-1339.
  61. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924-937.
  62. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-1846.
  63. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-265.
  64. Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 2021; 397: 592-604.
  65. Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022; 28: 2374-2380.
  66. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-1929.
  67. Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. JCO 2023; 41: 1213-1227.
  68. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Mene-zes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open- label, phase 3 trial. Lancet Oncol 2021; 22: 198-211.
  69. Zhou Q, Chen M, Wu G, Chang JH, Jiang O, Cui JW, et al. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res 2020; 9: 2008-2015.
  70. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386: 1973-1985.
  71. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019; 381: 2020-2031.
  72. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
  73. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddub- skaya E, et al. Nivolumab versus docetaxel in advanced squamous- cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
  74. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040-2051.
  75. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-2092.
  76. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-1833.
  77. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393: 1819-1830.
  78. O’Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022; 23: 1274-1286.
  79. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023; 389: 1672-1684.
  80. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med 2024; 390: 1756169.
  81. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023; 389: 491-503.
  82. Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Resp Med 2025; 13: 119-129.
  83. Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 2022; 23: 220-233.
  84. Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thor Oncol 2021; 16: 1512-1522.
  85. Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 2021; 7: 709.
  86. Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial. J Thor Oncol 2023; 18: 93-105.
  87. Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet 2025; 405: 2129-2143.
  88. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024; 391: 1313-1327.
  89. Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022; 7: 100408.
  90. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018; 379: 2220-2229.
  91. Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020; 21: 645-654.
  92. Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 2025; 393: 349-361.
  93. FENA, Federalna Novinska Agencija, ZZO HNŽ-a povećava visinu sudjelovanja u pravima osiguranika. Available from: https://fena.ba/article/1667688/zzo-hnz-a-povecava-visinu-sudjelovanja-u-pravima-osiguranika.
  94. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 339-357.
  95. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 5.2026. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed: 27.05.2026).
  96. Parić A, Tomić K, Begagić E, Naletilić MP, Glibić M, Srkalović G, et al. The prognostic and decision-making impact of KELIM CA-125 in patients with advanced ovarian cancer: a real-world study from Bosnia and Herzegovina. Eur J Obstet Gynecol Reprod Biol 2026; 324: 115245.
  97. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-1939.
  98. Tomic K, Begagic E, Voloder E, Naletilic MP, Jozic GB, Cale S, et al. Outcomes of extensive-stage small cell lung cancer treatment in a real-world clinical setting: a single-center experience. Contemp Oncol (Pozn) 2025; 29: 271-280.
  99. Bosna i Hercegovina, Federacija Bosne i Hercegovine, Kanton Sarajevo, Ministarstvo zdravstva, Osigurana sredstva za lijekove onkološkim pacijentima u Kantonu Sarajevo koji su na listi čekanja federalnog fonda solidarnosti. Available from: https://mz.ks.gov.ba/node/9174.
  100. Vrdoljak E, Bodoky G, Jassem J, Popescu R, Pirker R, Čufer T, et al. Expenditures on oncology drugs and cancer mortality-to-incidence ratio in central and eastern europe. Oncologist 2019; 24: e30-37.
  101. Hrvatski zavod za zdravstveno osiguranje, Objavljene liste lijekova, Osnovna lista lijekova (.xlsx). Available from: https://hzzo.hr/zdravstvena-zastita/objavljene-liste-lijekova.
  102. Republicki fond za zdravstveno osiguranje, Lista C. Lekovi sa posebnim režimom izdavanja. Available from: https://rfzo.rs/download/pravilnici/lekovi/Lista%20C_primena%20od%2031.10.2025..pdf.
  103. Zavod zdravstvenog osiguranja i reosiguranja Federacije Bosne i Hercegovine, Lijekovi koji se financiraju iz sredstava Fonda solidarnosti, Odluka o listi lijekova Fonda solidarnosti 05-07-2019.G. Available from: https://zzofbih.ba/wp-content/uploads/2022/06/Lista_lijekova_05_7_2019.pdf.
  104. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
  105. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398: 1344-1357.
  106. Singh S, Jaigirdar AA, Mulkey F, Cheng J, Hamed SS, Li Y, et al. FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer. Clin Cancer Res 2021; 27: 2378-2382.
  107. European Medicines Agency, Science Medicines Health, Zepzelca Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zepzelca#authorisation-details.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications